state antileishmani chemotherapy strongly compromise emerge drugresist leishmania revolt phenotype link parasite entries genome install frequent gene chromosome amplify caps fit gain directly select environment factor include present drug thu even though unique eukaryotic biology depend parasitespecif virus provide valid opportun chemotherapeut intervene strategy target parasite direct fashion like prone select resist review current discus limit onto drug discovery effort final propos new viable indirectly via meghan hostparasit interact parasitereleas ectokinas host epigenetic regal model cell signal transcript respect establish permits conduit intracellular survive 